SEARCH

SEARCH BY CITATION

References

  • Bacskai B. J., Kajdasz S. T., Christie R. H., Carter C., Games D., Seubert P., Schenk D. and Hyman B. T. (2001) Imaging of amyloid-beta deposits in brains of living mice permits direct observation of clearance of plaques with immunotherapy. Nat. Med. 7, 369372.
  • Bayer A. J., Bullock R., Jones R. W., Wilkinson D., Paterson K. R., Jenkins L., Millais S. B. and Donoghue S. (2005) Evaluation of the safety and immunogenicity of synthetic Abeta42 (AN1792) in patients with AD. Neurology 64, 94101.
  • Boche D., Zotova E., Weller R. O., Love S., Neal J. W., Pickering R. M., Wilkinson D., Holmes C. and Nicoll J. A. (2008) Consequence of Abeta immunization on the vasculature of human Alzheimer’s disease brain. Brain 131, 32993310.
  • Boutajangout A., Ingadottir J., Davies P. and Sigurdsson E. M. (2011) Passive immunization targeting pathological phospho-tau protein in a mouse model reduces functional decline and clears tau aggregates from the brain. J. Neurochem. 118(4), 65867.
  • Coley N., Andrieu S., Delrieu J., Voisin T. and Vellas B. (2009) Biomarkers in Alzheimer’s disease: not yet surrogate endpoints. Ann. N Y Acad. Sci. 1180, 119124.
  • Delrieu J., Piau A., Caillaud C., Voisin T. and Vellas B. (2011) Managing cognitive dysfunction through the continuum of Alzheimer’s disease: role of pharmacotherapy. CNS Drugs 25, 213226.
  • Dodel R., Neff F., Noelker C., Pul R., Du Y., Bacher M. and Oertel W. (2010) Intravenous immunoglobulins as a treatment for Alzheimer’s disease: rationale and current evidence. Drugs 70, 513528.
  • Fox N. C., Black R. S., Gilman S., Rossor M. N., Griffith S. G., Jenkins L. and Koller M. (2005) Effects of Abeta immunization (AN1792) on MRI measures of cerebral volume in Alzheimer disease. Neurology 64, 15631572.
  • Gilman S., Koller M., Black R. S. et al. (2005) Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. Neurology 64, 15531562.
  • Holmes C., Boche D., Wilkinson D. et al. (2008) Long-term effects of Abeta42 immunisation in Alzheimer’s disease: follow-up of a randomised, placebo-controlled phase I trial. Lancet 372, 216223.
  • Jack Jr C. R., Knopman D. S., Jagust W. J., Shaw L. M., Aisen P. S., Weiner M. W., Petersen R. C. and Trojanowski J. Q. (2010) Hypothetical model of dynamic biomarkers of the Alzheimer’s pathological cascade. Lancet Neurol. 9, 119128.
  • Janus C., Pearson J., McLaurin J. et al. (2000) A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer’s disease. Nature 408, 979982.
  • Magga J., Puli L., Pihlaja R. et al. (2010) Human intravenous immunoglobulin provides protection against Abeta toxicity by multiple mechanisms in a mouse model of Alzheimer’s disease. J. Neuroinflammation 7, 90.
  • Masliah E., Hansen L., Adame A., Crews L., Bard F., Lee C., Seubert P., Games D., Kirby L. and Schenk D. (2005) Abeta vaccination effects on plaque pathology in the absence of encephalitis in Alzheimer disease. Neurology 64, 129131.
  • Morgan D. (2006) Immunotherapy for Alzheimer’s disease. J. Alzheimers Dis. 9, 425432.
  • Nicoll J. A., Wilkinson D., Holmes C., Steart P., Markham H. and Weller R. O. (2003) Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report. Nat. Med. 9, 448452.
  • Orgogozo J. M., Gilman S., Dartigues J. F. et al. (2003) Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization. Neurology 61, 4654.
  • Racke M. M., Boone L. I., Hepburn D. L. et al. (2005) Exacerbation of cerebral amyloid angiopathy-associated microhemorrhage in amyloid precursor protein transgenic mice by immunotherapy is dependent on antibody recognition of deposited forms of amyloid beta. J. Neurosci. 25, 629636.
  • Rinne J. O., Brooks D. J., Rossor M. N. et al. (2010) 11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer’s disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study. Lancet Neurol. 9, 363372.
  • Salloway S., Sperling R., Gilman S. et al. (2009) A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease. Neurology 73, 20612070.
  • Schenk D., Barbour R., Dunn W. et al. (1999) Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 400, 173177.
  • Schroeter S., Khan K., Barbour R. et al. (2008) Immunotherapy reduces vascular amyloid-beta in PDAPP mice. J. Neurosci. 28, 67876793.
  • Siemers E. R., Friedrich S., Dean R. A., Gonzales C. R., Farlow M. R., Paul S. M. and Demattos R. B. (2010) Safety and changes in plasma and cerebrospinal fluid amyloid beta after a single administration of an amyloid beta monoclonal antibody in subjects with Alzheimer disease. Clin. Neuropharmacol. 33, 6773.
  • Sigurdsson E. M. (2008) Immunotherapy targeting pathological tau protein in Alzheimer’s disease and related tauopathies. J. Alzheimers Dis. 15, 157168.
  • Sperling R. A., Jack C. R., Jr, Black S. E. et al. (2011) Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: Recommendations from the Alzheimer’s Association Research Roundtable Workgroup. Alzheimers Dement. 7, 367385.
  • Wilcock D. M. and Colton C. A. (2009) Immunotherapy, vascular pathology, and microhemorrhages in transgenic mice. CNS Neurol. Disord. Drug Targets 8, 5064.